Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations

Current dry powder formulations for inhalation deposit a large fraction of their emitted dose in the upper respiratory tract where they contribute to off-target adverse effects and variability in lung delivery. The purpose of the current study is to design a new formulation concept that more effecti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Danforth P. Miller, Thomas E. Tarara, Jeffry G. Weers
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	respirable agglomerates inhaled corticosteroids ciclesonide particle engineering dry powder inhaler extrafine Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/f88f6d36841c437f9e8e7cbd4ec111e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f88f6d36841c437f9e8e7cbd4ec111e4
record_format	dspace
spelling	oai:doaj.org-article:f88f6d36841c437f9e8e7cbd4ec111e42021-11-25T18:41:12ZTargeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations10.3390/pharmaceutics131118551999-4923https://doaj.org/article/f88f6d36841c437f9e8e7cbd4ec111e42021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1855https://doaj.org/toc/1999-4923Current dry powder formulations for inhalation deposit a large fraction of their emitted dose in the upper respiratory tract where they contribute to off-target adverse effects and variability in lung delivery. The purpose of the current study is to design a new formulation concept that more effectively targets inhaled dry powders to the large and small airways. The formulations are based on adhesive mixtures of drug nanoparticles and nanoleucine carrier particles prepared by spray drying of a co-suspension of leucine and drug particles from a nonsolvent. The physicochemical and aerosol properties of the resulting formulations are presented. The formulations achieve 93% lung delivery in the Alberta Idealized Throat model that is independent of inspiratory flow rate and relative humidity. Largely eliminating URT deposition with a particle size larger than solution pMDIs is expected to improve delivery to the large and small airways, while minimizing alveolar deposition and particle exhalation.Danforth P. MillerThomas E. TararaJeffry G. WeersMDPI AGarticlerespirable agglomeratesinhaled corticosteroidsciclesonideparticle engineeringdry powder inhalerextrafinePharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1855, p 1855 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	respirable agglomerates inhaled corticosteroids ciclesonide particle engineering dry powder inhaler extrafine Pharmacy and materia medica RS1-441
spellingShingle	respirable agglomerates inhaled corticosteroids ciclesonide particle engineering dry powder inhaler extrafine Pharmacy and materia medica RS1-441 Danforth P. Miller Thomas E. Tarara Jeffry G. Weers Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations
description	Current dry powder formulations for inhalation deposit a large fraction of their emitted dose in the upper respiratory tract where they contribute to off-target adverse effects and variability in lung delivery. The purpose of the current study is to design a new formulation concept that more effectively targets inhaled dry powders to the large and small airways. The formulations are based on adhesive mixtures of drug nanoparticles and nanoleucine carrier particles prepared by spray drying of a co-suspension of leucine and drug particles from a nonsolvent. The physicochemical and aerosol properties of the resulting formulations are presented. The formulations achieve 93% lung delivery in the Alberta Idealized Throat model that is independent of inspiratory flow rate and relative humidity. Largely eliminating URT deposition with a particle size larger than solution pMDIs is expected to improve delivery to the large and small airways, while minimizing alveolar deposition and particle exhalation.
format	article
author	Danforth P. Miller Thomas E. Tarara Jeffry G. Weers
author_facet	Danforth P. Miller Thomas E. Tarara Jeffry G. Weers
author_sort	Danforth P. Miller
title	Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations
title_short	Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations
title_full	Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations
title_fullStr	Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations
title_full_unstemmed	Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations
title_sort	targeting of inhaled therapeutics to the small airways: nanoleucine carrier formulations
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f88f6d36841c437f9e8e7cbd4ec111e4
work_keys_str_mv	AT danforthpmiller targetingofinhaledtherapeuticstothesmallairwaysnanoleucinecarrierformulations AT thomasetarara targetingofinhaledtherapeuticstothesmallairwaysnanoleucinecarrierformulations AT jeffrygweers targetingofinhaledtherapeuticstothesmallairwaysnanoleucinecarrierformulations
_version_	1718410810559037440

Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations

Ejemplares similares